The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
== Other uses == Operation Snowcap (1987-1994) a U.S. counter-narcotics trafficking program Snowcaps (song), a 1999 song by Unwed Sailor Snow Cap (story) by Matthew S. Armstrong from the graphic novel anthology Flight, see List of volumes of Flight
=== Land reform === Segni's appointment seemed to halt Gullo's agrarian reform drive: between September 1946 and December 1947 issued two decrees that allowed landowners to reclaim unimproved lands. This secured the support of southern elites for the Christian Democrat party, enabling it to win the 18 April 1948 general elections. It increased the tension between the two factions and rekindled laborer occupation of uncultivated land. The Massacre of Melissa, took place in Calabria: on 24 October 1949, some 14,000 peasants from Catanzaro and Cosenza, accompanied by women, children and work animals, occupied the large latifundia and began planting. A group of agrarian Calabrian CD parliamentarians went to Rome, protesting and asking Scelba to use force against the peasants. Scelba sent Mobile Units (mechanized riot police), to Calabria, which stopped at Melissa, in Crotone, finding a large number of protesters on the Fragalà estate, owned by Baron Luigi Berlingeri. The land was supposed to be assigned to the municipality, but the Berlingeri family had usurped it. The peasants claimed at least half of it, but the baron was willing to cede only a third. On 29 October 1949, police, after demanding the crowd of peasants to leave, fired at eye level, wounding 15 wounded and killing 3: Giovanni Zito, Francesco Nigro, and Angelina Mauro. This massacre, combined with that of Portella della Ginestra, in Sicily, which took place on 1 May 1947, provoked strikes and peasant demonstrations throughout Italy.
=== Australia === From 2023, Juniper was cited in multiple reports examining the regulation of telehealth-based weight-loss services in Australia. The Royal Australian College of General Practitioners (RACGP) and medical regulators raised concerns about prescribing models relying on asynchronous or questionnaire-based assessments for injectable weight-loss medications. The TGA assessed whether online advertising by Juniper (and its competitors) could indirectly promote prescription-only medicines in breach of federal law. Between 2022 and 2024 they requested the removal of thousands of unlawful advertisements. In response to updated guidance from the Medical Board of Australia (MBA) restricting "tick-and-flick" prescribing, Eucalyptus Health said that its platforms would comply with requirements for real-time clinical consultation and enhanced verification. In July 2023, the TGA opened an investigation into whether email communications sent by Juniper to people on its contact list about the availability of Ozempic constituted unlawful advertising. Through 2024, the TGA proposed the removal of GLP-1 medicines from pharmacy compounding exemptions due to concerns that telehealth prescribing models were inconsistent with exemptions intended for individual patient use. They warned that compounded GLP-1 products were not subject to the same safety, quality, or adverse-event reporting requirements as TGA-approved medicines. Juniper was one of the companies prescribing them.
Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in [transgender] women is extremely sparse and based on low quality of evidence. Current evidence does not provide evidence that progestogens enhance breast development in [transgender] women. Neither do they prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions. Data on menstruating women shows there is no correlation between water retention, and levels of progesterone or estrogen. Despite this, some theorise progesterone might cause temporary breast enlargement due to local fluid retention, and may thus give a misleading appearance of breast growth. Aside from a hypothetical involvement in breast development, progestogens are not otherwise known to be involved in physical feminization.
== Early life and career == An Israeli-American, Ashkenazi earned a degree in finance and economics from the Hebrew University of Jerusalem and an MBA from Tel Aviv University. She worked in the financial services sector in Israel, including for Ma'alot Standard & Poor's and Bank Hapoalim.
Sources: en.wikipedia.org
D-amino-acid transaminase (EC 2.6.1.21) is an enzyme originally characterised from bacteria that catalyzes several reversible chemical reactions that interconvert specific D-amino acids and α-ketoglutaric acid with the corresponding α-keto acid and D-glutamic acid. For example, it can use D-alanine as a substrate:
== Treatment == There is no cure for HCP caused by the deficient activity of coproporphyrinogen oxidase. Treatment of the acute symptoms of HCP is the same as for other acute porphyrias. Intravenous hemin (as heme arginate or hematin) is the recommended therapy for acute attacks. Acute attacks can be severe enough to cause death if not treated quickly and correctly. Hospitalization is typically required for administration of hemin, and appropriate drug selection is key to avoid exacerbating symptoms with drugs that interact poorly with porphyrias. Proper drug selection is most difficult when it comes to treatment of the seizures that can accompany HCP, as most anti-seizure medications can make the symptoms worse. Gabapentin and levetiracetam are two anti-seizure drugs that are thought to be safe. In patients where management of symptoms is difficult even with hemin, liver transplant is an option before the symptoms have progressed to advanced paralysis. Combined liver and kidney transplants are sometimes undertaken in people with kidney failure. Long-term treatment of acute porphyrias is centered on the avoidance of acute attacks by eliminating precipitating factors, such as drugs, dietary changes, and infections. Females often have attacks coincident with their menstrual cycle, which can be managed effectively with hormonal birth control. Because of the reduced penetrance of HCP, family members of a patient may carry the same mutation without ever presenting with symptoms.
The brain requires approximately 3.3 ml of oxygen per 100 g of brain tissue per minute. Initially, the body responds to lowered blood oxygen by redirecting blood to the brain and increasing cerebral blood flow. Blood flow may increase up to twice the normal flow but no more. If the increased blood flow is sufficient to supply the brain's oxygen needs then no symptoms will result. However, if blood flow cannot be increased or if doubled blood flow does not correct the problem, symptoms of cerebral hypoxia will begin to appear. Mild symptoms include difficulties with complex learning tasks and reductions in short-term memory. If oxygen deprivation continues, cognitive disturbances and decreased motor control will result. The skin may also appear bluish (cyanosis) and heart rate increases. Continued oxygen deprivation results in fainting, long-term loss of consciousness, coma, seizures, cessation of brain stem reflexes, and brain death. Objective measurements of the severity of cerebral hypoxia depend on the cause. Blood oxygen saturation may be used for hypoxic hypoxia, but is generally meaningless in other forms of hypoxia. In hypoxic hypoxia 95–100% saturation is considered normal; 91–94% is considered mild and 86–90% moderate. Anything below 86% is considered severe. Cerebral hypoxia refers to oxygen levels in brain tissue, not blood. Blood oxygenation will usually appear normal in cases of hypemic, ischemic, and histotoxic cerebral hypoxia.
1993/3140) New Possibilities National Health Service Trust Dissolution Order 1993 (S.I. 1993/3141) Combined Probation Areas (Kent) Order 1993 (S.I. 1993/3142) Cayman Islands (Constitution) (Amendment) Order 1993 (S.I. 1993/3143) Child Abduction and Custody (Parties to Conventions) Order 1993 (S.I. 1993/3144) Hong Kong (Legislative Powers) (Amendment) Order 1993 (S.I. 1993/3145) Criminal Justice (Confiscation) (Northern Ireland) Order 1993 (S.I. 1993/3146) Criminal Justice Act 1988 (Designated Countries and Territories) (Amendment) (No. 2) Order 1993 (S.I. 1993/3147) Criminal Justice (International Co–operation) Act 1990 (Enforcement of Overseas Forfeiture Orders) (Amendment) (No. 2) Order 1993 (S.I. 1993/3148) Environmentally Sensitive Areas (Machair of the Uists and Benbecula, Barra and Vatersay) Designation Order 1993 (S.I. 1993/3149) Environmentally Sensitive Areas (Shetland Islands) Designation Order 1993 (S.I. 1993/3150) Registration of Births, Deaths and Marriages (Fees) (Scotland) Order 1993 (S.I. 1993/3151) Marriage Fees (Scotland) Regulations 1993 (S.I. 1993/3152) Registration of Births, Deaths, Marriages and Divorces (Fees) (Scotland) Regulations 1993 (S.I. 1993/3153) Maximum Number of Judges (Scotland) Order 1993 (S.I. 1993/3154) Criminal Justice (International Co-operation) Act 1990 (Enforcement of Overseas Forfeiture Orders) (Scotland) Amendment (No.2) Order 1993 (S.I. 1993/3155) Confiscation of the Proceeds of Drug Trafficking (Designated Countries and Territories) (Scotland) Amendment (No.2) Order 1993 (S.I.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.